

AMGEN INC  
Form 8-K  
January 24, 2008

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**  
**The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported)

January 24, 2008

**AMGEN INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**000-12477**  
(Commission  
File Number)

**95-3540776**  
(IRS Employer  
Identification No.)

**One Amgen Center Drive**

**Thousand Oaks, CA**  
(Address of principal executive offices)

**91320-1799**  
(Zip Code)

Registrant's telephone number, including area code

805-447-1000

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Edgar Filing: AMGEN INC - Form 8-K

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 2.02 Results of Operations and Financial Condition.**

On January 24, 2008, Amgen Inc. (the Company) issued a press release announcing its unaudited results of operations and financial condition for the three and twelve months ended December 31, 2007. The full text of the press release is set forth in Exhibit 99.1 attached hereto.

In its press release the Company included certain historical non-U.S. Generally Accepted Accounting Principles ( non-GAAP ) financial measures as defined in Regulation G promulgated by the Securities and Exchange Commission with respect to the three and twelve months ended December 31, 2007 and 2006. Reconciliations for such historical non-GAAP financial measures are attached to the press release set forth as Exhibit 99.1 attached hereto. The Company believes that its presentation of historical non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. These historical non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with U.S. Generally Accepted Accounting Principles ( GAAP ).

Three and twelve months ended December 31, 2007

For the three and twelve months ended December 31, 2007, the Company's adjustments to GAAP financial measures relate to amounts associated with the impact of expensing stock options in accordance with Statement of Financial Accounting Standards No. 123R ( SFAS No. 123R ), charges related to the Company's restructuring plan announced in August 2007 which include (i) severance and other separation costs partially offset by the reversal of previously accrued expenses for bonuses and stock-based compensation awards, which were forfeited as a result of the employees' termination, (ii) asset impairment charges incurred in connection with the rationalization of our worldwide manufacturing operations in order to gain cost efficiencies and, to a lesser degree, the moderation of the expansion of our research facilities, (iii) accelerated depreciation primarily resulting from our decision to accelerate closure of one of our Enbrel® commercial bulk production operations in connection with the rationalization of our worldwide network of manufacturing facilities, (iv) cost recoveries for certain restructuring expenses principally with respect to accelerated depreciation in connection with our co-promotion agreement with Wyeth and (v) charges principally related to loss accruals for leases for certain research and development facilities that will not be used in our business (collectively, the Restructuring Charges) and charges related to the Company's acquisitions of Alantox Pharmaceutical Holding, Inc. ( Alantox ) in July 2007 (the Alantox Acquisition), Ilypsa, Inc. ( Ilypsa ) in July 2007 (the Ilypsa Acquisition), Avidia, Inc. ( Avidia ) in October 2006 (the Avidia Acquisition), Abgenix, Inc. ( Abgenix ) in April 2006 (the Abgenix Acquisition), Tularik Inc. ( Tularik ) in August 2004 (the Tularik Acquisition) and Immunex Corporation ( Immunex ) in July 2002 (the Immunex Acquisition). In addition, the Company's adjustments to GAAP financial measures also relate to amounts associated with severance related expenses incurred in connection with the Company's acquisition of the remaining 51% ownership interest of Dompe Biotec, S.p.A (the Dompe Charge), the loss accrual for an ongoing commercial legal proceeding (the Legal Accrual), the write-off of inventory principally due to changing regulatory and reimbursement environments (the Inventory Charge), the write-off of the cost of a semi-completed manufacturing asset that will not be used due to a change in manufacturing strategy (the Manufacturing Charge), the income tax benefit recognized as a result of resolving certain non-routine transfer pricing issues with the Internal Revenue Service for prior periods (the Income Tax Benefit), the write-off of the pro rata portion of the deferred financing and related costs immediately charged to interest expense as a result of certain holders of our convertible notes due in 2032 exercising their March 1, 2007 put option and the related convertible notes being repaid in cash (the Convertible Notes Expense) as well as the tax effect of the adjustments discussed below excluding certain of the Restructuring Charges, certain components of the Inventory Charge, the non-cash expense associated with writing-off acquired in-process research and development related to the Alantox Acquisition and the Ilypsa Acquisition (the Alantox and Ilypsa Acquisition IPR&D Expense), the Manufacturing Charge and the Income Tax Benefit (the 2007 Tax Effect).

For the three and twelve months ended December 31, 2007, the Company reported non-GAAP financial results for cost of sales (excluding amortization of acquired intangible assets) ( COS ) expense, research and development ( R&D ) expense, selling, general and administrative ( SG&A ) expense and diluted shares used in the calculation of adjusted earnings per share. COS expense, R&D expense and SG&A expense were adjusted to exclude the effects of expensing stock options in accordance with SFAS No. 123R and the Restructuring Charges. Diluted shares used in the calculation of adjusted earnings per share were also adjusted to exclude the effects of adopting SFAS No.

123R. The Company believes that excluding the impact of expensing stock options and the related effects of adopting SFAS No. 123R provides supplemental measures that will facilitate comparisons between periods before and during when such expenses are incurred. The Company believes that excluding the Restructuring Charges provides supplemental measures that will facilitate comparisons between periods before, during and after such expenses are incurred.

For the twelve months ended December 31, 2007, COS expense was also adjusted to exclude the Inventory Charge, merger related expenses incurred due to the Abgenix Acquisition, primarily related to the incremental costs associated with recording inventory acquired at fair value which is in excess of our manufacturing cost (the Abgenix Merger Expense ) and the impact of the Manufacturing Charge. For the three and twelve months ended December 31, 2007, R&D expense was also adjusted to exclude the ongoing, non-cash amortization of the R&D technology intangible assets acquired with the Abgenix Acquisition and the Avidia Acquisition (the R&D Technology Intangible Assets Amortization ) and merger related expenses incurred due to the Alantos Acquisition, the Ilypsa Acquisition and the Tularik Acquisition primarily related to incremental costs associated with retention and/or integration (the Merger Retention Expense ). For the three and twelve months ended December 31, 2007, SG&A expense was also adjusted to exclude the Dompe Charge. The Company believes that excluding the Abgenix Merger Expense and the Merger Retention Expense provides supplemental measures that will facilitate comparisons between periods before, during and after such expenses are incurred. The Company believes that excluding the Inventory Charge, the Manufacturing Charge and the Dompe Charge provides supplemental measures that will facilitate comparisons between periods in which such items did not occur. The Company believes that excluding the R&D Technology Intangible Assets Amortization treats those assets as if the Company had developed them internally in the past, and thus provides a supplemental measure of profitability in which the Company's acquired intellectual property is treated in a comparable manner to its internally developed intellectual property.

For the three and twelve months ended December 31, 2007, the Company reported non-GAAP adjusted provisions for income taxes, adjusted net income and adjusted earnings per share that exclude all of the items identified above for the applicable periods for the reasons discussed above, the Restructuring Charges, the ongoing non-cash amortization of acquired intangible assets, primarily ENBREL, related to the Immunex Acquisition (the Immunex Intangible Assets Amortization ), the Legal Accrual and the 2007 Tax Effect. For the twelve months ended December 31, 2007, the Company also reported non-GAAP adjusted provision for income taxes, adjusted net income and adjusted earnings per share that exclude the Alantos and Ilypsa Acquisition IPR&D Expense, the impairment of a non-ENBREL related intangible asset previously acquired in the Immunex Acquisition (the Impairment Charge ), the Convertible Notes Expense and the Income Tax Benefit. The Company believes that excluding the Restructuring Charges provides a supplemental measure that will facilitate comparisons between periods before, during and after such expenses are incurred. The Company believes that excluding the Legal Accrual, the Alantos and Ilypsa Acquisition IPR&D Expense, the Impairment Charge, the Convertible Notes Expense, the Income Tax Benefit and the 2007 Tax Effect provides supplemental measures that will facilitate comparisons between periods in which such items did not occur. The Company believes that excluding the Immunex Intangible Assets Amortization treats those assets as if the Company had developed them internally in the past, and thus provides a supplemental measure of profitability in which the Company's acquired intellectual property is treated in a comparable manner to its internally developed intellectual property.

#### Three and twelve months ended December 31, 2006

For the three and twelve months ended December 31, 2006, the Company's adjustments to GAAP financial measures relate to amounts associated with the impact of expensing stock options in accordance SFAS No. 123R and with charges related to the Avidia Acquisition, the Abgenix Acquisition, the Tularik Acquisition and the Immunex Acquisition, as well as the tax effect of the adjustments discussed below excluding the non-cash expense associated with writing-off acquired in-process research and development related to the Abgenix Acquisition and the Avidia Acquisition (the Abgenix and Avidia Acquisition IPR&D Expense ) (the 2006 Tax Effect ).

For the three and twelve months ended December 31, 2006, the Company reported non-GAAP financial results for COS expense, R&D expense, SG&A expense and diluted shares used in the calculation of adjusted earnings per share. COS expense, R&D expense and SG&A expense were adjusted to exclude the effects of expensing stock options in accordance with SFAS No. 123R. Diluted shares used in the calculation of adjusted diluted earnings per share

were also adjusted to exclude the effects of adopting SFAS No. 123R. The Company believes that excluding the impact of expensing stock options and the related effects of adopting SFAS No. 123R provides supplemental measures that will facilitate comparisons between periods before and during when such expenses are incurred.

For the three and twelve months ended December 31, 2006, COS expense was also adjusted to exclude the Abgenix Merger Expense. R&D expense was also adjusted to exclude the ongoing, non-cash amortization of the R&D technology intangible asset acquired in the Abgenix Acquisition (the Abgenix R&D Technology Intangible Asset Amortization ) and the Abgenix Merger Expense. R&D and SG&A expense for the three and twelve months were also adjusted to exclude, where applicable, the merger related expenses incurred due to the Avidia Acquisition, the Abgenix Acquisition and the Tularik Acquisition primarily related to incremental costs associated with retention and/or integration (the 2006 Merger Retention Expense ). The Company believes that excluding the 2006 Merger Retention Expense and the Abgenix Merger Expense provides supplemental measures that will facilitate comparisons between periods before, during and after such expenses are incurred. The Company believes that excluding the Abgenix R&D Technology Intangible Asset Amortization treats the asset as if the Company had developed it internally in the past, and thus provides a supplemental measure of profitability in which the Company's acquired intellectual property is treated in a comparable manner to its internally developed intellectual property.

For the three and twelve months ended December 31, 2006, the Company reported non-GAAP adjusted provisions for income taxes, adjusted net income and adjusted earnings per share that exclude all of the items identified above for the applicable periods for the reasons discussed, the Abgenix and Avidia Acquisition IPR&D Expense, the Immunex Intangible Assets Amortization and the 2006 Tax Effect. For the twelve months ended December 31, 2006, the Company also reported non-GAAP adjusted provision for income taxes, adjusted net income and adjusted earnings per share that exclude the Impairment Charge. The Company believes that excluding the Abgenix and Avidia Acquisition IPR&D Expense and the Immunex Intangible Assets Amortization treats those assets as if the Company had developed them internally in the past, and thus provides a supplemental measure of profitability in which the Company's acquired intellectual property is treated in a comparable manner to its internally developed intellectual property. The Company believes that excluding the Impairment Charge and the 2006 Tax Effect provides supplemental measures that will facilitate comparisons between periods in which such items did not occur.

Due to the differing treatments of expensing stock options for the purpose of presenting adjusted earnings per share within and across industries, the Company also reported non-GAAP adjusted earnings per share including the impact of expensing stock options in accordance with SFAS No. 123R for the three and twelve months ended December 31, 2007 and December 31, 2006, as a convenience to investors.

#### **Item 9.01 Financial Statements and Exhibits.**

(c) Exhibits.

99.1 Press Release dated January 24, 2008

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMGEN INC.

Date: January 24, 2008

By: /s/ Robert A. Bradway  
Name: Robert A. Bradway  
Title: Executive Vice President

and Chief Financial Officer

**EXHIBIT INDEX**

**Exhibit**

<b>Number</b>	<b>Document Description</b>
99.1	Press release dated January 24, 2008